Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 192

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 192
---
 upon the conversion or exercise
of any warrant, right or other security which is issued as) a dividend, bonus shares or other distribution with respect to, or in exchange
for or in replacement of, any shares described through (i) – (iii) above, or IRA Registrable Securities, we are required to register
all the IRA Registrable Securities within 14 days of the receipt of such written request using our best efforts to effect, as soon as
practicable, the registration under the Securities Act of all IRA Registrable Securities that such holders request to be registered and
included in such registration we receive, provided that we shall not be required to effect such registration unless the estimated aggregate
offering price of all IRA Registrable Securities requested to be so registered is at least $2,000,000.

<div align='center'>117

DESCRIPTION OF SHARE CAPITAL</div>

The following description
of our share capital and provisions of our amended and restated articles of association which will be effective upon the completion of
this offering are summaries and do not purport to be complete. By becoming a shareholder in our Company, you will be deemed to have notice
of and consented to these provisions of our articles of association as amended and restated.

Authorized Capital

Upon the closing of this
offering, our authorized share capital will consist of Ordinary Shares, par value NIS 0.01 per share, of which Ordinary Shares will be
issued and outstanding (assuming that the Representative does not exercise its option to purchase additional Ordinary Shares).

All of our Ordinary Shares
have identical voting and other rights in all respects. All of our issued and outstanding Ordinary Shares are duly authorized, validly
issued, fully paid and non-assessable. Our amended and restated articles of association to be in effect upon completion of this offering
and the laws of the State of Israel do not restrict the ownership or voting of Ordinary Shares by non-residents of Israel, except with
respect to citizens of countries that are, or have been, in a state of war with Israel.

Preferred Shares

Upon the consummation of
this offering and the effectiveness of our amended and restated certificate of incorporation that will become effective immediately prior
to the consummation of this offering, we will have no authorized or outstanding preferred shares.

Each currently outstanding
Series A Preferred Share, Series B Preferred Share, Series C Preferred Share, Series D-1 Preferred Share and Series D-2 Preferred Share,
each a Preferred Share, is convertible,